Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII.

@article{Spencer2011LentiviralVP,
  title={Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII.},
  author={Harold T Spencer and Gabriela Denning and Richard E Gautney and Boro Dropuli{\'c} and Andre J Roy and Lajos Baranyi and Bagirath Gangadharan and Ernest T Parker and Pete Lollar and Christopher B. Doering},
  journal={Molecular therapy : the journal of the American Society of Gene Therapy},
  year={2011},
  volume={19 2},
  pages={
          302-9
        }
}
Patients with hemophilia A present with spontaneous and sometimes life-threatening bleeding episodes that are treated using blood coagulation factor VIII (fVIII) replacement products. Although effective, these products have limited availability worldwide due to supply limitations and product costs, which stem largely from manufacturing complexity. Current mammalian cell culture manufacturing systems yield around 100 µg/l of recombinant fVIII, with a per cell production rate of 0.05 pg/cell/day… CONTINUE READING
Highly Cited
This paper has 34 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

State of the art: gene therapy of haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia • 2016

References

Publications referenced by this paper.
Showing 1-10 of 19 references